Drugs for Paraganglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 78)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Doxazosin |
Approved |
Phase 3 |
|
74191-85-8 |
3157 |
Synonyms:
1 (4-amino-6,7-Dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine
1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
Alfamedin
Aliud brand OF doxazosin mesylate
Almirall brand OF doxazosin mesylate
Alpharma brand OF doxazosin mesylate
Alter brand OF doxazosin mesylate
apo Doxazosin
apo-Doxazosin
Apogepha brand OF doxazosin mesylate
Apotex brand OF doxazosin mesylate
AstraZeneca brand OF doxazosin mesylate
Azupharma brand OF doxazosin mesylate
Betapharm brand OF doxazosin mesylate
C02CA04
Cantabria brand OF doxazosin mesylate
Cardular
Cardura
Cardura XL
Cardura®|UK-3327427
Carduran
Carduran neo
Ciclum brand OF doxazosin mesylate
Cinfa brand OF doxazosin mesylate
combino Brand OF doxazosin mesylate
CT Arzneimittel brand OF doxazosin mesylate
CT, Doxazosin von
CT-Arzneimittel brand OF doxazosin mesylate
Diblocin
Doxa puren
Doxacor
Doxagamma
Doxamax
Doxa-puren
Doxatensa
DoxaUro
Doxazomerck
Doxazosin
Doxazosin al
Doxazosin apogepha
Doxazosin azu
Doxazosin beta
Doxazosin findusfit
Doxazosin heumann
Doxazosin klast
Doxazosin mesilate
Doxazosin mesylate
Doxazosin monohydrochloride
Doxazosin ratiopharm
Doxazosin stada
Doxazosin von CT
Doxazosin wolff
Doxazosina
|
Doxazosina alter
Doxazosina cinfa
Doxazosina combino pharm
Doxazosina geminis
Doxazosina normon
Doxazosina pharmagenus
Doxazosina ratiopharm
Doxazosina ur
Doxazosine
Doxazosin-ratiopharm
Doxazosinum
Doxazosin-wolff
Esparma brand OF doxazosin mesylate
FindusFit brand OF doxazosin mesylate
Geminis brand OF doxazosin mesylate
Gen doxazosin
Gen-doxazosin
Genpharm brand OF doxazosin mesylate
Heumann brand OF doxazosin mesylate
Hexal brand OF doxazosin mesylate
Juta brand OF doxazosin mesylate
Jutalar
Kade brand OF doxazosin mesylate
Linden brand OF doxazosin mesylate
Merck dura brand OF doxazosin mesylate
Mesylate, doxazosin
Monohydrochloride, doxazosin
MTW Brand OF doxazosin mesylate
MTW Doxazosin
MTW-Doxazosin
neo, Carduran
Normon brand OF doxazosin mesylate
novo Doxazosin
novo-Doxazosin
Novopharm brand OF doxazosin mesylate
Pfizer brand OF doxazosin mesylate
Pharmagenus brand OF doxazosin mesylate
Progandol neo
Q Pharm brand OF doxazosin mesylate
Q-Pharm brand OF doxazosin mesylate
ratio Doxazosin
ratio-Doxazosin
Ratiopharm brand OF doxazosin mesylate
Ratiopharm, doxazosina
Solvay brand OF doxazosin mesylate
Stadapharm brand OF doxazosin
TAD brand OF doxazosin mesylate
UK-33274
UK-3327427
Uriduct
Von CT, doxazosin
Wolff brand OF doxazosin mesylate
Wörwag brand OF doxazosin mesylate
Zoxan
|
|
2 |
|
Phenoxybenzamine |
Approved |
Phase 3 |
|
59-96-1 |
4768 |
Synonyms:
Dibenylene
Dibenyline
Dibenziran
Dibenzylin
Dibenzyline
Dibenzyline®|phenoxybenzamine hydrochloride
Dibenzyran
Esparma brand OF phenoxybenzamine hydrochloride
Fenossibenzamina
|
Fenoxibenzamina
Goldshield brand OF phenoxybenzamine hydrochloride
Hydrochloride, phenoxybenzamine
Link brand OF phenoxybenzamine hydrochloride
Phenoxybenzamine
Phenoxybenzamine hydrochloride
Phenoxybenzaminum
POB
Wellspring brand OF phenoxybenzamine hydrochloride
|
|
3 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
4 |
|
Antihypertensive Agents |
|
Phase 3 |
|
|
|
5 |
|
Adrenergic Antagonists |
|
Phase 3 |
|
|
|
6 |
|
Adrenergic alpha-Antagonists |
|
Phase 3 |
|
|
|
7 |
|
Adrenergic alpha-1 Receptor Antagonists |
|
Phase 3 |
|
|
|
8 |
|
Adrenergic Agents |
|
Phase 3 |
|
|
|
9 |
|
Vasodilator Agents |
|
Phase 3 |
|
|
|
10 |
|
Everolimus |
Approved |
Phase 2 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
11 |
|
Olaparib |
Approved |
Phase 2 |
|
763113-22-0 |
23725625 |
Synonyms:
1-(CYCLOPROPYLCARBONYL)-4-[5-[(3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL]-2-FLUOROBENZOYL]PIPERAZINE
4-(3-{[4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL]CARBONYL}-4-FLUOROBENZYL)PHTHALAZIN-1(2H)-ONE
AZ2281
AZ-2281
AZD2281
AZD-2281
AZD-2281|AZD2281|Lynparza®
|
KEYLYNK-010 COMPONENT OLAPARIB
KU-0059436
KU59436
KU-59436
Lynparza
OLAPARIB
OLAPARIB COMPONENT OF KEYLYNK-010
|
|
12 |
|
Temozolomide |
Approved, Investigational |
Phase 2 |
|
85622-93-1 |
5394 |
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
BRN 5547136
CCRG 81045
CCRG-81045
CCRIS 8996
m & b 39831
m And b 39831
m And b39831
m And b-39831
M&B 39831
M&B-39831
M-39831
MB 39831
Methazolastone
NSC 362856
NSC-362856
|
SCH 52365
SCH-52365
Temodal
Temodar
TEMOMEDAC
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide
Témozolomide
Temozolomide hexyl ester
Temozolomidum
Temozolomidum [Latin]
TMZ
TMZ Bioshuttle
TMZA-he
TMZ-Bioshuttle
|
|
13 |
|
Racepinephrine |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
51-43-4, 329-65-7 |
838 5816 |
Synonyms:
(−)-(R)-epinephrine
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-a-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]BENZYL ALCOHOL(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-Adrenaline
(−)-ADRENALINE
(-)-Epinephrine
(+-)-Adrenaline
(+-)-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(−)-ADRENALINE
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
2-(Methylamino)-1-(3,4-dihydroxyphenyl)ethanol
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-HYDROXY-2-METHYLAMINOETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]PYROCATECHOL
Acetate, epinephrine
Adnephrine
ADREN CO
ADRENACLICK
Adrenal
Adrenalin
adrenalin|Auvi-Q®|Epipen®|l-adrenaline|L-epinephrine|levoepinephrine
Adrenaline
Adrénaline
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
Adrenaline hydrochloride, racemic mixture
Adrenaline, racemic
Adrenaline, racemic mixture
adrenaline|epinephrine
Adrenine
Adrin
Allergan brand OF adrenaline hydrochloride
ANA-GUARD
Ana-kit
ANAPEN
ANAPHYLACTIC SHOCK DRUG KIT
ASMA-VYDRIN
ASTHMAHALER
Auvi-Q
Bird brand OF racepinefrine hydrochloride
Bosmin
Bronkaid mist
BROVON
Chelafrin
DL-Adrenaline
EMERADE
EPI E Z PEN JR
Epifrin
Epiglaufrin
Epinefrin
Epinefrina
Epinephran
Epinephrin
EPINEPHRINE
Epinephrine acetate
Epinephrine bitartrate
EPINEPHRINE HCL
Epinephrine hydrochloride
Epinephrine hydrochloride, racemic mixture
Epinephrine hydrogen tartrate
Epinephrine racemic
Epinephrine, racemic
Epinephrine, racemic mixture
Epinephrinum
Epipen
|
EPIPEN E Z PEN
Epipen JR
EPIPEN JR.
Epirenan
Epitrate
Eppy
Exadrin
Glauposine
GPPE INH SOLN
Hemisine
Hemostasin
Hemostatin
Hydrochloride, racepinephrine
Hypernephrin
Isoptoepinal
JEXT
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-DETHYLAMINOETHANOLCATECHOL
L-Epinephrine
L-Epirenamine
Levoepinephrine
LEVO-METHYLAMINOETHANOLCATECHOL
Levorenen
Levorenin
Levorenine
Levoreninum
L-Methylaminoethanolcatechol
Lyodrin
Lyophrin
Medihaler-epi
Methylarterenol
Micronefrin
Micronephrine
Mixture adrenaline, racemic
Mixture epinephrine, racemic
Mucidrina
Nephridine
Nieraline
NSC-62786
Paranephrin
Primatene
Primatene mist
R-(-)-Epinephrine
Racemic adrenaline
Racemic epinephrine
Racemic mixture adrenaline
Racemic mixture epinephrine
Racepinefrina
Racepinefrine
Racepinefrinum
Racepinephrine
Racepinephrine hydrochloride
Renaglandin
Renaleptine
Renalina
Renoform
Renostypticin
Renostyptin
RIDDOBRON
RIDDOFAN
RYBARVIN
Scurenaline
Simplene
SOLN MADE TO RYBARVIN FOR
Styptirenal
Supracapsulin
Supranephrane
Suprarenaline
Suprarenin
Surrenine
Sus-phrine
SUS-PHRINE SULFITE FREE
SUS-PHRINE SULFITE-FREE
SYMJEPI
Takamina
TWINJECT
TWINJECT 0.15
TWINJECT 0.3
Vaponefrin
Vasoconstrictine
Vasotonin
|
|
14 |
|
Axitinib |
Approved, Investigational |
Phase 2 |
|
319460-85-0 |
6450551 |
Synonyms:
AG 013736
AG 013736|AG-013736|AG013736|Inlyta®
AG013736
AG-013736
AG-13736
|
AXITINIB
AXITINIBUM
INLYTA
N-METHYL-2-({3-[(E)-2-(PYRIDIN-2-YL)VINYL]-1H-INDAZOL-6-YL}SULFANYL)BENZAMIDE
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
|
|
15 |
|
Nivolumab |
Approved |
Phase 1, Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
16 |
|
Lanreotide |
Approved |
Phase 2 |
|
108736-35-2 |
71349 6918011 |
Synonyms:
188Re-Lanreotide
2-{[(19-{[2-amino-1-hydroxy-3-(naphthalen-2-yl)propylidene]amino}-10-(4-aminobutyl)-6,9,12,15,18-pentahydroxy-16-[(4-hydroxyphenyl)methyl]-13-[(1H-indol-3-yl)methyl]-7-(propan-2-yl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-4-yl)(hydroxy)methylidene]amino}-3-hydroxybutanimidate
2-Naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide
BIM 23014
BIM 23014|DC 13-116|lanreotide acetate|Somatuline®
DC 13-116
Lanreotida
Lanreotide
Lanreotide acetate
Lanreotide acetic acid
Lanreotide-SR
|
L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide
Nal-cyclo(cys-tyr-TRP-lys-val-cys)THR-NH2
Nal-cyclo(cys-tyr-TRP-lys-val-cys)-THR-NH2
Naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide
Naphthyl-cyclo(cys-tyr-TRP-lys-val-cys)THR-NH2
Somatulin
Somatulina
Somatuline
SOMATULINE AUTOGEL
SOMATULINE LA
|
|
17 |
|
Atezolizumab |
Approved, Investigational |
Phase 2 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
18 |
|
Talazoparib |
Approved, Investigational |
Phase 2 |
|
1207456-01-6 |
135565082 |
Synonyms:
BMN 673
BMN-673
BMN-673|BMN673|Talzenna®
|
LT-673
TALAZOPARIB
Talzenna
|
|
19 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
20 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
21 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
22 |
|
Azacitidine |
Approved, Investigational |
Phase 2 |
|
320-67-2 |
9444 |
Synonyms:
4-Amino-1-b-D-ribofuranosyl-S-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-S-triazin-2(1H)-one
4-Amino-1-β-D-ribofuranosyl-S-triazin-2(1H)-one
5 Azacytidine
5 AZC
5-AZAC
5-azacytidine
Azacitidina
|
Azacitidine
Azacitidinum
Azacytidine
LADAKAMYCIN
NSC-102816
Pharmion brand OF azacitidine
U-18496
Vidaza
|
|
23 |
|
Octreotide |
Approved, Investigational |
Phase 1, Phase 2 |
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-19-{[(2R)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
19-[(2-Amino-1-hydroxy-3-phenylpropylidene)amino]-10-(4-aminobutyl)-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
Compound 201 995
Compound 201995
Compound 201-995
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulphide
DRG-0115|Mycapssa®|Sandostatin®|SMS 201,995
Octreotida
Octreotide
Octreotide acetate
OCTREOTIDE ACETATE (PRESERVATIVE FREE)
OCTREOTIDE ACETATE PRESERVATIVE FREE
Octreotide acetate salt
Octreotidum
|
Octrotide
Sandostatin
SANDOSTATIN LAR
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SMS 201-995
SMS 201-995 AC
SMS-201-995
SMS-201-995 AC
SMS-201995-AC
SMS995
SMS-995
|
|
24 |
|
Arginine |
Approved, Investigational, Nutraceutical |
Phase 2 |
|
74-79-3 |
6322 |
Synonyms:
(2S)-2-Amino-5-(carbamimidamido)pentanoate
(2S)-2-Amino-5-(carbamimidamido)pentanoic acid
(2S)-2-AMINO-5-(DIAMINOMETHYLIDENEAMINO)PENTANOIC ACID
(2S)-2-AMINO-5-[(DIAMINOMETHYLIDENE)AMINO]PENTANOIC ACID
(2S)-2-Amino-5-guanidinopentanoate
(2S)-2-Amino-5-guanidinopentanoic acid
(2S)-2-AMINO-5-GUANIDINO-PENTANOIC ACID
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoic acid
(S)-2-Amino-5-guanidinopentanoate
(S)-2-Amino-5-guanidinopentanoic acid
(S)-2-Amino-5-guanidinovalerate
(S)-2-Amino-5-guanidinovaleric acid
2-Amino-5-guanidinovalerate
2-Amino-5-guanidinovaleric acid
5-[(Aminoiminomethyl)amino]-L-norvaline
Arg
Arginina
Arginine
|
Arginine hydrochloride
Arginine, L isomer
Arginine, L-isomer
DL Arginine acetate, monohydrate
DL-Arginine acetate, monohydrate
Hydrochloride, arginine
L Arginine
L-(+)-Arginine
L-a-Amino-D-guanidinovalerate
L-a-Amino-D-guanidinovaleric acid
L-alpha-Amino-delta-guanidinovalerate
L-alpha-Amino-delta-guanidinovaleric acid
L-Arg
L-Arginin
L-ARGININE
L-Isomer arginine
Monohydrate DL-arginine acetate
N5-(Aminoiminomethyl)-L-ornithine
NSC-206269
R
|
|
25 |
|
Lysine |
Approved, Nutraceutical |
Phase 2 |
|
56-87-1 |
5962 |
Synonyms:
(+)-S-Lysine
(S)-2,6-Diaminohexanoate
(S)-2,6-Diamino-hexanoate
(S)-2,6-Diaminohexanoic acid
(S)-2,6-Diamino-hexanoic acid
(S)-a,e-Diaminocaproate
(S)-a,e-Diaminocaproic acid
(S)-a,epsilon-Diaminocaproate
(S)-a,epsilon-Diaminocaproic acid
(S)-alpha,epsilon-Diaminocaproate
(S)-alpha,epsilon-Diaminocaproic acid
(S)-Lysine
(S)-Α,epsilon-diaminocaproate
(S)-Α,epsilon-diaminocaproic acid
(S)-α,ε-diaminocaproic acid
2,6-Diaminohexanoate
2,6-Diaminohexanoic acid
6-Amino-aminutrin
6-Amino-L-norleucine
6-Ammonio-L-norleucine
Acetate, lysine
alpha-Lysine
|
a-Lysine
Aminutrin
Enisyl
H-Lys-OH
K
L Lysine
L-(+)-Lysine
L-2,6-Diainohexanoate
L-2,6-Diainohexanoic acid
L-2,6-Diaminocaproate
L-2,6-Diaminocaproic acid
L-Lys
L-Lysin
L-Lysine
Lys
Lysina
Lysine
Lysine acetate
Lysine acid
Lysine hydrochloride
Lysinum
|
|
26 |
|
D-Phenylalanine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 2 |
|
63-91-2, 673-06-3 |
6140 71567 |
Synonyms:
(-)-beta-Phenylalanine
(6S)-Tetrahydrofolate
(6S)-Tetrahydrofolic acid
(6S)-THFA
(L)-Phenylalanine
(S)-(-)-Phenylalanine
(S)-2-Amino-3-phenylpropanoate
(S)-2-Amino-3-phenylpropanoic acid
(S)-2-Amino-3-phenylpropionate
(S)-2-AMINO-3-PHENYLPROPIONIC ACID
(S)-a-Amino-b-phenylpropionate
(S)-a-Amino-b-phenylpropionic acid
(S)-alpha-Aminobenzenepropanoate
(S)-alpha-Amino-benzenepropanoate
(S)-alpha-Aminobenzenepropanoic acid
(S)-alpha-Amino-benzenepropanoic acid
(S)-alpha-Amino-beta-phenylpropionate
(S)-ALPHA-AMINO-BETA-PHENYLPROPIONIC ACID
(S)-alpha-Aminohydrocinnamate
(S)-alpha-Aminohydrocinnamic acid
(S)-Phenylalanine
(S)-Α-amino-β-phenylpropionate
(S)-Α-amino-β-phenylpropionic acid
3-PHENYL-L-ALANINE
5,6,7,8-Tetrahydrofolate
5,6,7,8-Tetrahydrofolic acid
a-Amino-b-phenylpropionate
a-Amino-b-phenylpropionic acid
alpha-Amino-beta-phenylpropionate
alpha-Amino-beta-phenylpropionic acid
alpha-Aminohydrocinnamate
|
alpha-Aminohydrocinnamic acid
beta-Phenylalanine
beta-Phenyl-alpha-alanine
BETA-PHENYL-L-ALANINE
b-Phenyl-L-alanine
D-(+)-phenylalanine
DL-Phenylalanine
Endorphenyl
F
FEMA NO. 3585
Fenilalanina
L-2-Amino-3-phenylpropionate
L-2-Amino-3-phenylpropionic acid
L-Isomer phenylalanine
L-PHE
L-Phenylalanine
NSC-79477
PHE
Phenylalamine
Phenylalanin
Phenylalanine
Phenyl-alanine
Phenylalanine, L isomer
Phenylalanine, L-isomer
Phenylalaninum
Tetrahydrofolate
THF
Α-amino-β-phenylpropionate
Α-amino-β-phenylpropionic acid
Î’-PHENYL-L-ALANINE
|
|
27 |
|
Guadecitabine |
Investigational |
Phase 2 |
|
929901-49-5 |
112499969 |
Synonyms:
|
28 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
29 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
30 |
|
Alkylating Agents |
|
Phase 2 |
|
|
|
31 |
|
Antineoplastic Agents, Alkylating |
|
Phase 2 |
|
|
|
32 |
|
Poly(ADP-ribose) Polymerase Inhibitors |
|
Phase 2 |
|
|
|
33 |
|
Epinephryl borate |
|
Phase 1, Phase 2 |
|
|
|
34 |
|
Fluorodeoxyglucose F18 |
|
Phase 2 |
|
|
|
35 |
|
Endothelial Growth Factors |
|
Phase 2 |
|
|
|
36 |
|
Mitogens |
|
Phase 2 |
|
|
|
37 |
|
Vaccines |
|
Phase 1, Phase 2 |
|
|
|
38 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
39 |
|
Edotreotide lutetium LU-177 |
|
Phase 2 |
|
|
|
40 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
41 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
42 |
|
Antibodies |
|
Phase 2 |
|
|
|
43 |
|
Immune Checkpoint Inhibitors |
|
Phase 2 |
|
|
|
44 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
45 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
46 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
47 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
48 |
|
Antineoplastic Agents, Hormonal |
|
Phase 1, Phase 2 |
|
|
|
49 |
|
Gastrointestinal Agents |
|
Phase 1, Phase 2 |
|
|
|
50 |
|
Sirolimus |
Approved, Investigational |
Phase 1 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
Interventional clinical trials:
(show top 50)
(show all 70)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors |
Completed |
NCT01344356 |
Phase 4 |
|
2 |
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors |
Unknown status |
NCT01373736 |
Phase 3 |
123I-meta-iodobenzylguanidine |
3 |
Randomized Controlled Trial of Preoperative Alpha Blockade for Pheochromocytoma |
Recruiting |
NCT03176693 |
Phase 3 |
Phenoxybenzamine;Doxazosin |
4 |
A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma |
Unknown status |
NCT00874614 |
Phase 2 |
|
5 |
A Phase 2 Study of Dovitinib in Adults With Advanced Malignant Pheochromocytoma or Paraganglioma |
Completed |
NCT01635907 |
Phase 2 |
Dovitinib |
6 |
Phase II Study of RAD001monotherapy in Patients With Unresectable Pheochromocytoma or Extra-adrenal Paraganglioma or Non-functioning Carcinoid |
Completed |
NCT01152827 |
Phase 2 |
RAD001 |
7 |
A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma |
Completed |
NCT00458952 |
Phase 1, Phase 2 |
Ultratrace Iobenguane (MIBG) I 131 |
8 |
Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma |
Completed |
NCT03008369 |
Phase 2 |
Lenvatinib |
9 |
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma |
Completed |
NCT01967576 |
Phase 2 |
Axitinib (AG-013736) |
10 |
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL) |
Completed |
NCT01371201 |
Phase 2 |
Sunitinib;Placebo |
11 |
A Phase II Study of 131I-labeled Metaiodobenzylguanidine (MIBG) for Treatment of Patients With Metastatic or Unresectable Pheochromocytoma and Related Tumors |
Completed |
NCT01413503 |
Phase 2 |
|
12 |
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors |
Completed |
NCT01560260 |
Phase 2 |
Linsitinib |
13 |
A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas |
Recruiting |
NCT02302833 |
Phase 2 |
Cabozantinib S-malate |
14 |
A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma |
Recruiting |
NCT04394858 |
Phase 2 |
Olaparib;Temozolomide |
15 |
A Phase 2 Study of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma |
Recruiting |
NCT04860700 |
Phase 2 |
anlotinib hydrochloride |
16 |
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma |
Recruiting |
NCT03839498 |
Phase 2 |
Axitinib |
17 |
A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma |
Recruiting |
NCT04187404 |
Phase 1, Phase 2 |
|
18 |
A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial. |
Recruiting |
NCT05133349 |
Phase 2 |
Anlotinib |
19 |
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors |
Recruiting |
NCT04924075 |
Phase 2 |
Belzutifan |
20 |
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma |
Recruiting |
NCT03206060 |
Phase 2 |
Lu-177-DOTATATE;Ga-68-DOTATATE;F-18-FDG;Amino Acid solution |
21 |
Exploratory Phase II Study of LAnreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA) |
Recruiting |
NCT03946527 |
Phase 2 |
Lanreotide |
22 |
A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL) |
Recruiting |
NCT04711135 |
Phase 2 |
Lutetium [177Lu] oxodotreotide/dotatate |
23 |
A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored Study to Determine the Safety and Effectiveness of Lu-177 DOTATOC in Adult Subjects With Somatostatin Receptor Expressing Pulmonary, Pheochromocytoma, paragangliomUnknown Primary, and Thymus Neuroendocrine Tumors (PUTNET) or Any Other Non-.GEP-NET. |
Recruiting |
NCT04276597 |
Phase 2 |
177Lu-DOTATOC |
24 |
Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study |
Recruiting |
NCT04400474 |
Phase 2 |
Cabozantinib 40 mg |
25 |
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide |
Recruiting |
NCT05142241 |
Phase 2 |
Talazoparib;Temozolomide |
26 |
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
Recruiting |
NCT02834013 |
Phase 2 |
|
27 |
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors |
Active, not recruiting |
NCT02721732 |
Phase 2 |
|
28 |
A Investigator Initiated Phase II Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma |
Active, not recruiting |
NCT00843037 |
Phase 2 |
Sunitinib |
29 |
A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors |
Not yet recruiting |
NCT05636618 |
Phase 1, Phase 2 |
[212Pb]VMT-α-NET, |
30 |
A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma |
Terminated |
NCT01340794 |
Phase 2 |
Pazopanib Hydrochloride |
31 |
A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer |
Terminated |
NCT03165721 |
Phase 2 |
SGI-110 (guadecitabine) |
32 |
Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies |
Terminated |
NCT02177773 |
Phase 1, Phase 2 |
Gallium Ga 68-Edotreotide |
33 |
A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma |
Withdrawn |
NCT04106843 |
Phase 2 |
Lutetium Lu 177 Dotatate |
34 |
Phase I Trial of Peptide Receptor Radiotherapy (PRRT) With 177Lu-DOTA-tyr3-Octreotate (177Lu-DOTATATE) in Children and Adolescents With Neuroendocrine Tumor or Pheochromocytoma/Paraganglioma |
Withdrawn |
NCT03923257 |
Phase 1, Phase 2 |
177Lu-DOTA-tyr3-OCTREOTATE |
35 |
Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors. |
Completed |
NCT01155258 |
Phase 1 |
temsirolimus;vinorelbine ditartrate |
36 |
A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors |
Completed |
NCT01076530 |
Phase 1 |
vorinostat;temozolomide |
37 |
Phase 1 Study Evaluating the Safety, Distribution, Metabolism, and Radiation Dosimetry of ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid |
Completed |
NCT00339131 |
Phase 1 |
Ultratrace iobenguane I 131 |
38 |
Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma |
Completed |
NCT01204476 |
Phase 1 |
Everolimus;Octreotide Acetate |
39 |
Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and Paraganglioma |
Recruiting |
NCT00004847 |
Phase 1 |
([18F]-DOPA);([18F]-6F-DA) |
40 |
A Phase I Trial of Vandetanib Combined With 131I-mIBG Radiotherapy in Patients With Neuroendocrine Tumours, Advanced Phaeochromocytoma and Paraganglioma |
Withdrawn |
NCT01941849 |
Phase 1 |
Vandetanib |
41 |
Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation: Monocentric Prospective Study |
Unknown status |
NCT02186678 |
|
|
42 |
Expanded Access Program of AZEDRA (Ultratrace Iobenguane I131) in Subjects With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma: A Sub-study of Protocol MIP-IB12B |
Approved for marketing |
NCT02961491 |
|
Ultratrace Iobenguane I131 |
43 |
Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma |
Approved for marketing |
NCT01377532 |
|
131 I-Metaiodobenzylguanidine (131 I-MIBG) |
44 |
Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot |
Completed |
NCT00875407 |
|
|
45 |
Clinical Application of New Pheochromocytoma Markers: INSERM Pilot Study of the Specificity of Elevated Plasma EM66 Concentrations in Patients With Pheochromocytoma or Paraganglioma Compared to Patients With Essential Hypertension |
Completed |
NCT01022515 |
|
|
46 |
Prospective Cohort Study of Objective Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma and Their Reversal Following Curative Surgery |
Completed |
NCT05082311 |
|
|
47 |
Evaluation Des méthodes de dépistage du Paragangliome héréditaire Chez Les Sujets prédisposés génétiquement |
Completed |
NCT00188019 |
|
|
48 |
Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Spine Metastases and Primary Spine Tumors |
Completed |
NCT01347307 |
|
|
49 |
Familial Investigations of Childhood Cancer Predisposition |
Recruiting |
NCT03050268 |
|
|
50 |
Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue: Proof of Concept Against PET-CT in Patients Affected by Pheochomocytoma and/or Paraganglioma |
Recruiting |
NCT04605848 |
|
|
Cochrane evidence based reviews: paraganglioma
|